about
Thunder and lightning: immunotherapy and oncolytic viruses collideInterferon-gamma Added During Bacillus Calmette-Guerin Induced Dendritic Cell Maturation Stimulates Potent Th1 Immune ResponsesIntravesical immunotherapy in nonmuscle invasive bladder cancerApplications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapyBacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer.Mycobacterium tuberculosis complex enhances susceptibility of CD4 T cells to HIV through a TLR2-mediated pathwayDiscriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG).Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins.Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha.Fatal systemic reaction after multiple doses of intravesical bacillus Calmette-Guérin for polyposis.Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteinsImmunotherapy in genitourinary malignancies.Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patientsClosely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells.Thermostable direct hemolysin downregulates human colon carcinoma cell proliferation with the involvement of E-cadherin, and β-catenin/Tcf-4 signaling.Immune selection in neoplasia: towards a microevolutionary model of cancer development.An armamentarium of wart treatmentsAntitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity.Activation of anti-tumor immune response and reduction of regulatory T cells with Mycobacterium indicus pranii (MIP) therapy in tumor bearing mice.Lung cancer immunotherapy.Anti-cancer properties of gastropodan hemocyanins in murine model of colon carcinoma.Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancerIdentification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A.Immunotherapy for bladder cancer.Recombinant BCG as a vaccine vehicle to protect against tuberculosis.Optimal epitope composition after antigen screening using a live bacterial delivery vector: application to TRP-2.Bugs as drugs for cancer.Microorganisms and cancer: quest for a therapy.Supernatants from lymphocytes stimulated with Bacillus Calmette-Guerin can modify the antigenicity of tumours and stimulate allogeneic T-cell responses.CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophilsIntravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancerRole of urothelial cells in BCG immunotherapy for superficial bladder cancerManipulation of BCG vaccine: a double-edged sword.Challenges facing adjuvants for cancer immunotherapy.Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune responseSmoking-induced immune deviation contributes to progression of bladder and other cancers.A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitroEnhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model.The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence.
P2860
Q24597894-3F870852-DE7F-4F6F-9267-8B9D6D6C5A7CQ24805658-7A33A3D0-5DD3-4249-BA92-734944AEBC3FQ26775979-7BF28746-580D-4177-A0D6-70C868FEF7E9Q26798372-460AEBAA-E33D-4B5D-BB2C-3568D993EB8FQ28387398-0FE6D017-785E-40CB-9CDC-4ADFE94AB9A1Q28728928-21F50DF4-F50A-4E57-B837-D428EA515A79Q33284823-0A344CAA-C805-4306-8A68-65371B47825DQ33304879-D82DB282-D6BC-4F6D-BDDA-DD0E42886DDFQ33319305-0EE55FCA-F132-4937-8D64-A2DD0B4E94EFQ33335258-C2FB6558-7BB6-4F26-848D-5EA1EDD90A95Q33485621-10C0050F-8315-4C1C-908B-23194AE56A3EQ33593800-63B54622-D4AC-42B5-B43C-BBFB8E27BE5CQ33684090-7E37D175-93C4-483D-962B-D652C2B81F80Q33793700-6D7E51E2-B5BE-4AEF-B0DC-2011CD357D61Q33916259-029CC650-CFE4-4F5F-8A8B-851044BB597BQ33948688-E33DC48F-5ECE-457D-A15C-88650E57F484Q34001838-4E5C6EC3-C35A-43B9-B068-232480140230Q34023502-E52F49FF-7386-42F5-A98A-090B5E962397Q34044931-974B81BC-19E7-457B-95DE-DB284CF48E41Q34146503-FB1501B9-6640-4C4D-BC8C-4FDDA7F2156EQ34184980-00861C48-EED1-4844-9BFC-81B7A6CC7407Q34203675-17E2A669-006D-44DE-A956-7A2E5001B688Q34409699-A1698E5E-2FAD-4608-9888-4A74B0EFC00AQ34477444-EBCC4430-C8FB-4925-A442-73AA4EC75D6DQ34518560-6D3A2F69-98B8-4329-9630-33320CC1DAD2Q34558230-5C8AC9BC-711C-4F26-92B7-0088EFEB9987Q34842154-25D91BED-AD24-457B-A01B-7E4BD71D8AFFQ34983790-2DC21C85-3E42-4FEB-A937-090AD2071CA8Q35287568-2F5F466C-C67B-4189-AAE3-BFC53FC3744FQ35676736-0A6812F0-1254-433A-AA6C-8D20DDE2C2C6Q35689498-B4911AF9-1C95-477D-97DC-90072501BBF9Q35690511-0BE80C99-0581-4DD8-850C-52B179DFEF99Q35842140-4787D193-F14E-4500-8408-92E85D34CA9EQ35904315-041DAC97-93AD-4A2E-9D12-41E23BEB8328Q35953773-D5469F34-B456-4C7D-9EA4-8E5178B5EA02Q36038379-B11FFAA7-8959-496F-A5FD-DED557CB2D2EQ36060362-0EA0EDEE-1CC0-4DF5-93D2-8BDE537BF5FDQ36110948-B28E320A-9A12-472B-B172-D8144807DF4FQ36142577-D0AB28F7-DBE7-4AEB-9568-82F76BF20B26Q36249221-59E53C10-0156-437C-878C-14008BA9254E
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
BCG immunotherapy of bladder cancer: 20 years on.
@ast
BCG immunotherapy of bladder cancer: 20 years on.
@en
type
label
BCG immunotherapy of bladder cancer: 20 years on.
@ast
BCG immunotherapy of bladder cancer: 20 years on.
@en
prefLabel
BCG immunotherapy of bladder cancer: 20 years on.
@ast
BCG immunotherapy of bladder cancer: 20 years on.
@en
P1433
P1476
BCG immunotherapy of bladder cancer: 20 years on
@en
P2093
A B Alexandroff
P304
P356
10.1016/S0140-6736(98)07422-4
P407
P577
1999-05-01T00:00:00Z